ClinicalTrials.gg
RecruitingNCT07862933Updated Oct 16, 2026

AI-Based Conversational Social Support for Older Adults With Heart Failure

An interventional study of AI-Based Conversational Social Support and Community Social Participation in Heart Failure, sponsored by Chang Gung University of Science and Technology. Recruiting at 2 sites in Taiwan. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by Chang Gung University of Science and Technology · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Registered 10 months after the study started (first participant enrolled Nov 2025, registered Oct 2026).
  • Started Nov 2025; still recruiting 1 year later.
Updated Oct 16, 2026Primary outcomes revisedNewly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
174
Allocation
Non-randomized
Ages
60 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 137 studies in Heart Failure with a site in Taiwan — 30 open to participants now, 39 under way, 14 of them phase 3. Heart Failure · Taiwan.

Planned enrollment
52nd of 101
174 · median 177
Started
2025
with 9 others
No phase
49 of 137
11 open now
Primary completion
2028-07
later than 26 of 38 live
Registered
137th of 137
by date

Among the 137 studies in Heart Failure with a site in Taiwan, this one is the 52nd largest by planned enrollment of the 101 interventional ones that give a count, is one of 10 that started in 2025, is one of 49 with no phase, reaches primary completion later than 26 of the 38 other live ones, and was the 137th registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

30 of the 137 studies in Heart Failure with a site in Taiwan are open now. Recruiting first, the newest first:

24 more — sign in →

All 30 open studies →

A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 60 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 137 studies in Heart Failure with a site in Taiwan, or all of them as a file.
02

Study summary

This three-year study aims to investigate gender differences in social frailty and evaluate the effects of an artificial intelligence (AI)-based conversational social-support intervention among older adults with chronic heart failure (CHF).

The study plans to enroll 300-500 adults aged 60 years or older from four Chang Gung Memorial Hospital branches in Taiwan.

In the first phase, researchers will assess participants' clinical characteristics, sarcopenia, physical activity, and physical, psychological, and social frailty. The study will examine gender differences and identify factors associated with social frailty.

In the second phase, 174 participants are planned to be assigned to three groups: an AI-based conversational social-support group, a community social participation group, and a control group. The AI group will engage in daily 15-30-minute app-based conversations, while the community group will be encouraged to participate in regular social activities. The control group will maintain routine activities.

The third phase will assess longer-term changes in social frailty, emotional well-being, physical activity, and health outcomes, with follow-up assessments at 1, 3, 6, and 12 months after the intervention.

Read the detailed description

This study combines an initial cross-sectional assessment with an embedded intervention trial and longitudinal follow-up.

Phase 1: Baseline assessment

Clinical information and standardized assessments will be collected to examine gender differences in sarcopenia, physical activity, and multidimensional frailty among older adults with chronic heart failure. Structural equation modeling will be used to investigate factors and pathways associated with social frailty.

Phase 2: Intervention

The protocol plans to enroll 174 participants in three groups of 58:

  1. AI-Based Conversational Social-Support Intervention: Participants will be instructed to use an AI-based conversational application for 15-30 minutes daily. The intervention includes conversational support and emotional monitoring. Training, language support, and tablets or internet connectivity will be provided when needed.
  2. Community Social Participation: Participants will be encouraged to attend regular social activities to enhance social interaction, with continued care and telephone follow-up.
  3. Control: Participants will maintain their routine activities.

Clinical and questionnaire-based assessments will be conducted before and after the intervention to evaluate changes in emotional state, physical activity, social frailty, and other health outcomes.

Phase 3: Longitudinal follow-up

Follow-up assessments are planned at 1, 3, 6, and 12 months after the intervention to examine the sustainability of intervention effects and potential gender differences. Assessments include standardized questionnaires and relevant clinical measures.

03

Conditions studied

  • Heart Failure

Keywords

  • Chronic Heart Failure
  • Gender Differences
  • Artificial Intelligence
  • Conversational Social Support
  • Frailty
  • Physical Activity
  • Older Adults
  • Longitudinal Study
04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants aged 60 years or older.
  2. Diagnosis of chronic heart failure (CHF).
  3. Ability to communicate effectively in Mandarin or Taiwanese.

Exclusion criteria

Exclusion Criteria:

  1. Unstable heart failure.
  2. Severe comorbidities, such as end-stage renal disease, advanced hepatic dysfunction, or terminal .
  3. Severe cognitive deficits that impede the ability to provide or participate in study interventions.
  4. Uncorrected visual or hearing impairments that hinder effective communication or interaction with the AI-based conversational social-support intervention.
  5. Active psychiatric conditions, including major depression or psychosis, that could interfere with study participation or adherence.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
174 participants (estimated)

Study arms

  • Experimental
    AI Conversational Support Group

    Participants in this group will receive an AI-based conversational social-support intervention delivered via a tablet.

    Behavioral: AI-Based Conversational Social Support

  • Active comparator
    Community Social Participation Group

    Participants in this group will be encouraged to attend regular community social activities to enhance social interaction. Care and follow-up will also be provided by telephone.

    Behavioral: Community Social Participation

  • No intervention
    Control Group

    Participants in this group will maintain their routine activities without receiving the AI-based conversational social-support intervention or the community social participation intervention.

Interventions

  • BehavioralAI-Based Conversational Social Support

    Participants will receive an AI-based conversational social-support intervention delivered via a tablet. The intervention is designed to provide social interaction and support for older adults with heart failure.

  • BehavioralCommunity Social Participation

    Participants will be encouraged to attend regular community social activities to enhance social interaction, with continued care and follow-up by telephone.

06

What researchers measure

Primary outcomes

  1. Change in Social Frailty Score

    Change in social frailty will be assessed using the five-item Makizako Social Frailty Index. Each item is scored as 0 or 1, yielding a total score ranging from 0 to 5. Higher scores indicate greater social frailty and therefore worse outcomes. Changes in scores will be compared among the AI-based conversational social-support intervention group, community social participation group, and control group.

    Time frame: Baseline and 1, 3, 6, and 12 months after intervention

07

Study locations

2 of 2 sites recruiting
  • New Taipei Municipal Tucheng Hospital (Built and Operated by Chang Gung Medical Foundation)
    New Taipei City, New Taipei City 236, Taiwan
    Recruiting
  • Chang Gung Memorial Hospital, Linkou
    Taoyuan, Taoyuan City 333, Taiwan
    Recruiting
08

References and documents

Publications

  • Son YJ, Shim DK, Seo EK, Won MH. Gender differences in the impact of frailty on 90-day hospital readmission in heart failure patients: a retrospective cohort study. Eur J Cardiovasc Nurs. 2021 Jun 29;20(5):485-492. doi: 10.1093/eurjcn/zvaa028. Epub 2021 Jan 6. PubMed 34038526 ↗
  • Fear K, Gleber C. Shaping the Future of Older Adult Care: ChatGPT, Advanced AI, and the Transformation of Clinical Practice. JMIR Aging. 2023 Sep 13;6:e51776. doi: 10.2196/51776. PubMed 37703085 ↗
  • Kastner M, Herrington I, Makarski J, Amog K, Bain T, Evangelista V, Hayden L, Gruber A, Sutherland J, Sirkin A, Perrier L, Graham ID, Greiver M, Honsberger J, Hynes M, Macfarlane C, Prasaud L, Sklar B, Twohig M, Liu B, Munce S, Marr S, O'Neill B, Papaioannou A, Seaton B, Straus SE, Dainty K, Holroyd-Leduc J. Interventions that have potential to help older adults living with social frailty: a systematic scoping review. BMC Geriatr. 2024 Jun 15;24(1):521. doi: 10.1186/s12877-024-05096-w. PubMed 38879489 ↗
  • Ijaz N, Buta B, Xue QL, Mohess DT, Bushan A, Tran H, Batchelor W, deFilippi CR, Walston JD, Bandeen-Roche K, Forman DE, Resar JR, O'Connor CM, Gerstenblith G, Damluji AA. Interventions for Frailty Among Older Adults With Cardiovascular Disease: JACC State-of-the-Art Review. J Am Coll Cardiol. 2022 Feb 8;79(5):482-503. doi: 10.1016/j.jacc.2021.11.029. PubMed 35115105 ↗
  • Talha KM, Pandey A, Fudim M, Butler J, Anker SD, Khan MS. Frailty and heart failure: State-of-the-art review. J Cachexia Sarcopenia Muscle. 2023 Oct;14(5):1959-1972. doi: 10.1002/jcsm.13306. Epub 2023 Aug 16. PubMed 37586848 ↗
  • Watanabe A, Katano S, Yano T, Nagaoka R, Numazawa R, Honma S, Yamano K, Fujisawa Y, Ohori K, Kouzu H, Ishigo T, Katayose M, Hashimoto A, Furuhashi M. Loss of perceived social role, an index of social frailty, is an independent predictor of future adverse events in hospitalized patients with heart failure. Front Cardiovasc Med. 2022 Dec 20;9:1051570. doi: 10.3389/fcvm.2022.1051570. eCollection 2022. PubMed 36606289 ↗
  • Uchmanowicz I, Pasieczna AH, Wojta-Kempa M, Gobbens RJJ, Mlynarska A, Faulkner KM, Czapla M, Szczepanowski R. Physical, Psychological and Social Frailty Are Predictive of Heart Failure: A Cross-Sectional Study. J Clin Med. 2022 Jan 23;11(3):565. doi: 10.3390/jcm11030565. PubMed 35160017 ↗
  • Goto T, Kishimoto T, Fujiwara S, Shirayama Y, Ichikawa T. Social frailty as a predictor of all-cause mortality and functional disability: a systematic review and meta-analysis. Sci Rep. 2024 Feb 10;14(1):3410. doi: 10.1038/s41598-024-53984-3. PubMed 38341512 ↗
  • Makizako H, Tsutsumimoto K, Shimada H, Arai H. Social Frailty Among Community-Dwelling Older Adults: Recommended Assessments and Implications. Ann Geriatr Med Res. 2018 Mar;22(1):3-8. doi: 10.4235/agmr.2018.22.1.3. Epub 2018 Mar 31. PubMed 32743237 ↗
  • Maeda D, Matsue Y, Kagiyama N, Jujo K, Saito K, Kamiya K, Saito H, Ogasahara Y, Maekawa E, Konishi M, Kitai T, Iwata K, Wada H, Hiki M, Dotare T, Sunayama T, Kasai T, Nagamatsu H, Ozawa T, Izawa K, Yamamoto S, Aizawa N, Wakaume K, Oka K, Momomura SI, Minamino T. Sex differences in the prevalence and prognostic impact of physical frailty and sarcopenia among older patients with heart failure. Nutr Metab Cardiovasc Dis. 2022 Feb;32(2):365-372. doi: 10.1016/j.numecd.2021.10.012. Epub 2021 Oct 23. PubMed 34893406 ↗
  • Chen LK, Woo J, Assantachai P, Auyeung TW, Chou MY, Iijima K, Jang HC, Kang L, Kim M, Kim S, Kojima T, Kuzuya M, Lee JSW, Lee SY, Lee WJ, Lee Y, Liang CK, Lim JY, Lim WS, Peng LN, Sugimoto K, Tanaka T, Won CW, Yamada M, Zhang T, Akishita M, Arai H. Asian Working Group for Sarcopenia: 2019 Consensus Update on Sarcopenia Diagnosis and Treatment. J Am Med Dir Assoc. 2020 Mar;21(3):300-307.e2. doi: 10.1016/j.jamda.2019.12.012. Epub 2020 Feb 4. PubMed 32033882 ↗
  • Archer SH, Lee CS, Gupta N, Roberts Davis M, Hiatt SO, Purnell JQ, Tibbitts D, Winters-Stone K, Denfeld QE. Sex differences in the impact of physical frailty on outcomes in heart failure. Heart Lung. 2023 Sep-Oct;61:66-71. doi: 10.1016/j.hrtlng.2023.04.014. Epub 2023 May 6. PubMed 37156061 ↗
  • Davis MR, Lee CS, Corcoran A, Gupta N, Uchmanowicz I, Denfeld QE. Gender differences in the prevalence of frailty in heart failure: A systematic review and meta-analysis. Int J Cardiol. 2021 Jun 15;333:133-140. doi: 10.1016/j.ijcard.2021.02.062. Epub 2021 Feb 28. PubMed 33657397 ↗
  • Keshvani N, Pandey A. Beyond Physical Impairment: The Role of Social Frailty in Heart Failure. J Am Heart Assoc. 2021 Sep 7;10(17):e022187. doi: 10.1161/JAHA.121.022187. Epub 2021 Sep 2. No abstract available. PubMed 34472383 ↗
  • Jujo K, Kagiyama N, Saito K, Kamiya K, Saito H, Ogasahara Y, Maekawa E, Konishi M, Kitai T, Iwata K, Wada H, Kasai T, Nagamatsu H, Ozawa T, Izawa K, Yamamoto S, Aizawa N, Yonezawa R, Oka K, Makizako H, Momomura SI, Matsue Y. Impact of Social Frailty in Hospitalized Elderly Patients With Heart Failure: A FRAGILE-HF Registry Subanalysis. J Am Heart Assoc. 2021 Sep 7;10(17):e019954. doi: 10.1161/JAHA.120.019954. Epub 2021 Sep 2. PubMed 34472374 ↗

Individual participant data

Plan to share: No — Individual participant data will not be shared with researchers outside the study team due to participant privacy and confidentiality considerations.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Jul 2028, 32 months after the start.

Of 1,119 non-industry interventional studies with no phase under Heart Failure, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 50. This study's planned 32 months is above that.

Counting every sponsor, half of 1,355 studies reached it within 31 months; a quarter within 16 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 1, 2026
First posted
Oct 7, 2026
StartActual
Nov 5, 2025
Primary completionEst.
Jul 2028
CompletionEst.
Jul 31, 2028
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary outcomes
1 description edited
What changed in the outcomes
  • DescriptionChange in Social Frailty Score: how it is measured was reworded
Oct 16, 2026
Registered
First appeared on the registry
Oct 7, 2026
Show all 2 updates
  1. Oct 16, 2026
    Primary outcomes 1 description edited
    What changed in the outcomes
    • DescriptionChange in Social Frailty Score: how it is measured was reworded
    + 2 other changes: index terms and conditions
  2. Oct 7, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07862933
Lead sponsor
Chang Gung University of Science and Technology
Responsible party
Sponsor
First posted
Oct 7, 2026
Start date
Nov 5, 2025
Primary completion
Jul 2028 (estimated)
Completion
Jul 31, 2028 (estimated)
Last update
Oct 16, 2026

Study contacts

Jeng Wang, PhD
Contact
jengwang@mail.cgust.edu.tw
+886 03-2118999#3435
Jeng Wang, PhD
principal investigator · Chang Gung University of Science and Technology, Department of Nursing

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion